Answers are grounded in this paper and cite their sources.
The N-methyl-d-aspartate receptor (NMDAR) is a ligated-gated cation channel that mediates excitatory synaptic transmission in the central nervous system. These receptors are involved in important brain functions and have been implicated in many neuropathological conditions. Four GluN2 subunits assemble with GluN1 to produce a series of NMDAR subtypes that are expressed in different subpopulations of neurons at different times. Among the GluN2 subunits, the GluN2D-containing NMDARs are highly expressed in inhibitory interneurons, which are key targets for drug development. Positive allosteric modulators (PAMs) have been proposed to be useful in several neuropsychiatric indications, including schizophrenia and depression. We have previously discovered EU 1622-240, a novel GluN2B/C/D-biased PAM with favorable oral bioavailability, CNS exposure, and anxiolytic activity in rodents. However, it was a P-gp inhibitor, cleared rapidly, and poorly absorbed in vivo. Through an extensive SAR, we now present EU 1622-287 with improved solubility, oral bioavailability, brain exposure, and anxiolytic effects.
No takes yet. Share an insight, caveat, or question.
Akins et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: